Huntington National Bank Purchases 366 Shares of Agilent Technologies Inc (NYSE:A)

Huntington National Bank lifted its position in shares of Agilent Technologies Inc (NYSE:A) by 33.7% during the 3rd quarter, HoldingsChannel reports. The firm owned 1,451 shares of the medical research company’s stock after acquiring an additional 366 shares during the period. Huntington National Bank’s holdings in Agilent Technologies were worth $111,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in A. Edgestream Partners L.P. bought a new stake in Agilent Technologies in the second quarter worth $2,616,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its holdings in Agilent Technologies by 81.0% in the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 157,403 shares of the medical research company’s stock worth $11,753,000 after acquiring an additional 70,426 shares in the last quarter. Skandinaviska Enskilda Banken AB publ boosted its holdings in Agilent Technologies by 2.6% in the second quarter. Skandinaviska Enskilda Banken AB publ now owns 66,135 shares of the medical research company’s stock worth $4,938,000 after acquiring an additional 1,654 shares in the last quarter. HighTower Advisors LLC boosted its holdings in Agilent Technologies by 1,183.0% in the second quarter. HighTower Advisors LLC now owns 122,800 shares of the medical research company’s stock worth $9,132,000 after acquiring an additional 113,229 shares in the last quarter. Finally, Prentiss Smith & Co. Inc. boosted its holdings in Agilent Technologies by 484.9% in the second quarter. Prentiss Smith & Co. Inc. now owns 58,428 shares of the medical research company’s stock worth $4,363,000 after acquiring an additional 48,438 shares in the last quarter.

Agilent Technologies stock traded up $0.73 during mid-day trading on Friday, reaching $76.64. 1,157,853 shares of the stock traded hands, compared to its average volume of 2,235,919. The stock has a market capitalization of $23.38 billion, a PE ratio of 27.47, a price-to-earnings-growth ratio of 1.88 and a beta of 1.42. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.13 and a quick ratio of 1.72. Agilent Technologies Inc has a 12-month low of $62.00 and a 12-month high of $82.27. The business’s 50-day moving average is $75.70 and its 200-day moving average is $72.83.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, August 14th. The medical research company reported $0.76 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.04. The company had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.24 billion. Agilent Technologies had a return on equity of 20.00% and a net margin of 21.06%. Agilent Technologies’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.67 earnings per share. Equities analysts anticipate that Agilent Technologies Inc will post 3.08 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, October 23rd. Investors of record on Tuesday, October 1st were given a dividend of $0.164 per share. This represents a $0.66 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date was Monday, September 30th. Agilent Technologies’s dividend payout ratio (DPR) is presently 23.66%.

Several research firms have commented on A. Zacks Investment Research downgraded Agilent Technologies from a “buy” rating to a “hold” rating and set a $75.00 target price on the stock. in a report on Monday, August 19th. Bank of America downgraded Agilent Technologies from a “buy” rating to a “neutral” rating and set a $76.00 price target on the stock. in a report on Tuesday, July 16th. Robert W. Baird reaffirmed an “outperform” rating and set a $82.00 price target (up from $79.00) on shares of Agilent Technologies in a report on Thursday, August 15th. Needham & Company LLC upped their price target on Agilent Technologies to $92.00 and gave the company a “buy” rating in a report on Monday, August 19th. Finally, UBS Group downgraded Agilent Technologies from a “buy” rating to a “neutral” rating and set a $82.00 price target on the stock. in a report on Friday, October 18th. Seven equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $84.00.

In other Agilent Technologies news, Director Heidi Fields sold 4,000 shares of the company’s stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $78.56, for a total value of $314,240.00. Following the completion of the sale, the director now owns 53,287 shares in the company, valued at $4,186,226.72. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Michael R. Mcmullen sold 24,635 shares of the company’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $77.50, for a total value of $1,909,212.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,635 shares of company stock valued at $2,507,293.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

See Also: After-Hours Trading

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies Inc (NYSE:A).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.